Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4606 to 4620 of 8219 results

  1. Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used routinely or according to clinical need in children and young people who are at Gross Motor Function Classification System (GMFCS) level I, II or III?

    Recommendation ID CG145/3 Question Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when

  2. Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe emphysema is inadequate in quantity and quality. Therefore the procedure should only be used in the context of  research .

    Recommendation ID IPG652/1 Question Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe

  3. Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia interventions with standard care.

    Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in

  4. Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for clinical trials of management of Lyme disease?

    Recommendation ID NG95/1 Question Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for

  5. Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma?

    Recommendation ID NG14/02 Question Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment

  6. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    Recommendation ID NG14/01 Question Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response

  7. Detection and management of respiratory disorders in primary and community care:- Can detection and management of respiratory disorders in adults with cerebral palsy be improved in primary and community care?

    Recommendation ID NG119/3 Question Detection and management of respiratory disorders in primary and community care:- Can detection and

  8. Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum antibiotic therapy, without adversely affecting outcomes?

    Recommendation ID CG191/4 Question Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum

  9. Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people with atrial fibrillation according to baseline risk factors and treatment?

    Recommendation ID NG196/7 Question Stroke risk assessment: Can routine data from UK primary care databases clarify stroke risk in people

  10. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Recommendation ID CG186/5 Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory

  11. Weight loss for managing pelvic floor dysfunction: Can weight loss reduce symptoms of pelvic floor dysfunction in women who are overweight or obese?

    Recommendation ID NG210/11 Question Weight loss for managing pelvic floor dysfunction: Can weight loss reduce symptoms of pelvic floor

  12. What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia compared with other pharmacological treatments?

    Recommendation ID CG173/3 Question What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia

  13. Carbamazepine for treating trigeminal neuralgia:- What is the clinical and cost effectiveness of carbamazepine as initial treatment for trigeminal neuralgia compared with other pharmacological treatments?

    Recommendation ID CG173/3 Question Carbamazepine for treating trigeminal neuralgia:- What is the clinical and cost effectiveness of carbamazepine